The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
The theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,580
Cruickshank, K., Riste, L., Anderson, S. G., Wright, J. S., Dunn, G., & Gosling, R. G. (2002) · Circulation · doi:10.1161/01.cir.0000033824.02722.f7 · Cited by 1,531
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Association of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Roman, M. J., Devereux, R. B., Kizer, J. R., Lee, E. T., Galloway, J. M., Ali, T., Umans, J. G., & Howard, B. V. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.089078 · Cited by 1,080
Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., Woodward, M., MacMahon, S., Turnbull, F., Hillis, G. S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00805-3 · Cited by 980
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Self-citationBolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Eight-year weight losses with an intensive lifestyle intervention: The look AHEAD study
The Look AHEAD Research Group (2014) · Obesity · doi:10.1002/oby.20662 · Cited by 842
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Self-citationHostetter, T. H., Rennke, H. G., & Brenner, B. M. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90490-9 · Cited by 796
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Self-citationGlomerular hemodynamics in experimental diabetes mellitus
Hostetter, T. H., Troy, J. L., & Brenner, B. M. (1981) · Kidney International · doi:10.1038/ki.1981.33 · Cited by 790
Lv, J., Neal, B., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., Wang, H., MacMahon, S., Turnbull, F., Hillis, G., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001293 · Cited by 777
Rahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., & Brown, J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3427 · Cited by 777
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Gorboulev, V., Schürmann, A., Vallon, V., Kipp, H., Jaschke, A., Klessen, D., Friedrich, A., Scherneck, S., Rieg, T., Cunard, R., et al. (2012) · Diabetes · doi:10.2337/db11-1029 · Cited by 687
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Self-citationKanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Paget's Disease of the Mandible
Patel, M. B., & Bhalla, A. (2008) · New England Journal of Medicine · doi:10.1056/nejmicm066227 · Cited by 610
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Nauck, M. A., Del Prato, S., Meier, J. J., Durán-García, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2011) · Diabetes Care · doi:10.2337/dc11-0606 · Cited by 528
Lavalle-González, F. J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., & Meininger, G. (2013) · Diabetologia · doi:10.1007/s00125-013-3039-1 · Cited by 492
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
Yale, J. ‐., Bakris, G., Cariou, B., Yue, D., David‐Neto, E., Xi, L., Figueroa, K., Wajs, E., Usiskin, K., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12090 · Cited by 487
Vallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483
Schernthaner, G., Gross, J. L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., Kawaguchi, M., Canovatchel, W., & Meininger, G. (2013) · Diabetes Care · doi:10.2337/dc12-2491 · Cited by 480
Nelson, R. G., Bennett, P. H., Beck, G. J., Tan, M., Knowler, W. C., Mitch, W. E., Hirschman, G. H., & Myers, B. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611283352203 · Cited by 477
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443
Self-citationKetone body metabolism and cardiovascular disease
Cotter, D. G., Schugar, R. C., & Crawford, P. A. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00646.2012 · Cited by 440
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396
Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370
Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · Diabetes Care · doi:10.2337/dc13-3055 · Cited by 363
Wilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc09-0517 · Cited by 363
Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K. D., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-0355 · Cited by 359
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358
Self-citationDapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Komoroski, B., Vachharajani, N., Boulton, D., Kornhauser, D., Geraldes, M., Li, L., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.251 · Cited by 350
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Stein, P., Desai, M., Shaw, W., Jiang, J., Vercruysse, F., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.007 · Cited by 341
Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.
Rossetti, L., Shulman, G. I., Zawalich, W., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113157 · Cited by 330
Self-citationGlomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes
Ruggenenti, P., Porrini, E. L., Gaspari, F., Motterlini, N., Cannata, A., Carrara, F., Cella, C., Ferrari, S., Stucchi, N., Parvanova, A., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2189 · Cited by 321
Rieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D. R., Thomson, S. C., Koepsell, H., & Vallon, V. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00518.2013 · Cited by 310
Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D., & McMurray, J. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3956-x · Cited by 309
Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., Shalayda, K., Demarest, K., & Rothenberg, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01406.x · Cited by 297
DeFronzo, R. A., Lewin, A., Patel, S., Liu, D., Kaste, R., Woerle, H. J., & Broedl, U. C. (2015) · Diabetes Care · doi:10.2337/dc14-2364 · Cited by 296
Self-citationSGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Abdul-Ghani, M., Del Prato, S., Chilton, R., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dc16-0041 · Cited by 295
Self-citationDeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293
Self-citationVrhovac, I., Balen Eror, D., Klessen, D., Burger, C., Breljak, D., Kraus, O., Radović, N., Jadrijević, S., Aleksic, I., Walles, T., et al. (2015) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1619-7 · Cited by 290
Rosenstock, J., Hansen, L., Zee, P., Li, Y., Cook, W., Hirshberg, B., & Iqbal, N. (2015) · Diabetes Care · doi:10.2337/dc14-1142 · Cited by 290
Henry, R. R., Thakkar, P., Tong, C., Polidori, D., & Alba, M. (2015) · Diabetes Care · doi:10.2337/dc15-1730 · Cited by 285
Stumvoll, M., Chintalapudi, U., Perriello, G., Welle, S., Gutierrez, O., & Gerich, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118314 · Cited by 279
Katsuno, K., Fujimori, Y., Takemura, Y., Hiratochi, M., Itoh, F., Komatsu, Y., Fujikura, H., & Isaji, M. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110296 · Cited by 267
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Self-citationRenal glucose production and utilization: new aspects in humans
Stumvoll, M., Meyer, C., Mitrakou, A., Nadkarni, V., & Gerich, J. E. (1997) · Diabetologia · doi:10.1007/s001250050745 · Cited by 257
Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes
Levelt, E., Mahmod, M., Piechnik, S. K., Ariga, R., Francis, J. M., Rodgers, C. T., Clarke, W. T., Sabharwal, N., Schneider, J. E., Karamitsos, T. D., et al. (2016) · Diabetes · doi:10.2337/db15-0627 · Cited by 254
Abdul-Ghani, M. A., DeFronzo, R. A., & Norton, L. (2013) · Diabetes · doi:10.2337/db13-0604 · Cited by 249
Self-citationDel Prato, S., Nauck, M., Durán‐Garcia, S., Maffei, L., Rohwedder, K., Theuerkauf, A., & Parikh, S. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12459 · Cited by 233
Bode, B., Stenlöf, K., Harris, S., Sullivan, D., Fung, A., Usiskin, K., & Meininger, G. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12428 · Cited by 229
Leiter, L. A., Yoon, K.-H., Arias, P., Langslet, G., Xie, J., Balis, D. A., Millington, D., Vercruysse, F., Canovatchel, W., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc13-2762 · Cited by 227
Mogensen, C. E. (1971) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517109090668 · Cited by 221
Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
Oliva, R. V., & Bakris, G. L. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.02.003 · Cited by 219
Tuttle, K. R., Bruton, J. L., Perusek, M. C., Lancaster, J. L., Kopp, D. T., & DeFronzo, R. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106063242304 · Cited by 217
Self-citationLjunggren, Ö., Bolinder, J., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01630.x · Cited by 215
DeFronzo, R. A., Stonehouse, A. H., Han, J., & Wintle, M. E. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02941.x · Cited by 213
Self-citationDapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Daniele, G., Xiong, J., Solis-Herrera, C., Merovci, A., Eldor, R., Tripathy, D., DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2016) · Diabetes Care · doi:10.2337/dc15-2688 · Cited by 213
Self-citationDevenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A. (2012) · Obesity · doi:10.1038/oby.2012.59 · Cited by 212
Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus
Song, P., Onishi, A., Koepsell, H., & Vallon, V. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1168808 · Cited by 194
Freitas, H. S., Anhê, G. F., Melo, K. F. S., Okamoto, M. M., Oliveira-Souza, M., Bordin, S., & Machado, U. F. (2008) · Endocrinology · doi:10.1210/en.2007-1088 · Cited by 192
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Merovci, A., Mari, A., Solis, C., Xiong, J., Daniele, G., Chavez-Velazquez, A., Tripathy, D., Urban McCarthy, S., Abdul-Ghani, M., & DeFronzo, R. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3472 · Cited by 186
Self-citationEFFECT OF DIABETES AND INSULIN ON THE MAXIMUM CAPACITY OF THE RENAL TUBULES TO REABSORB GLUCOSE 1
Farber, S. J., Berger, E. Y., & Earle, D. P. (1951) · Journal of Clinical Investigation · doi:10.1172/jci102424 · Cited by 185
Powell, D. R., Smith, M., Greer, J., Harris, A., Zhao, S., DaCosta, C., Mseeh, F., Shadoan, M. K., Sands, A., Zambrowicz, B., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203364 · Cited by 184
Role of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man.
Groop, L. C., Bonadonna, R. C., Shank, M., Petrides, A. S., & DeFronzo, R. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115005 · Cited by 181
Self-citationZhang, L., Feng, Y., List, J., Kasichayanula, S., & Pfister, M. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01216.x · Cited by 171
Kahn, B. B., Shulman, G. I., DeFronzo, R. A., Cushman, S. W., & Rossetti, L. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115031 · Cited by 171
Self-citationArakawa, K., Ishihara, T., Oku, A., Nawano, M., Ueta, K., Kitamura, K., Matsumoto, M., & Saito, A. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703829 · Cited by 160
Stenlöf, K., Cefalu, W. T., Kim, K.-A., Jodar, E., Alba, M., Edwards, R., Tong, C., Canovatchel, W., & Meininger, G. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.850066 · Cited by 158
Improved glycemic control in mice lacking Sglt1 and Sglt2
Powell, D. R., DaCosta, C. M., Gay, J., Ding, Z.-M., Smith, M., Greer, J., Doree, D., Jeter-Jones, S., Mseeh, F., Rodriguez, L. A., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00439.2012 · Cited by 158
Škrtić, M., & Cherney, D. Z. I. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000084 · Cited by 156
Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes.
Bonadonna, R. C., Del Prato, S., Saccomani, M. P., Bonora, E., Gulli, G., Ferrannini, E., Bier, D., Cobelli, C., & DeFronzo, R. A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116592 · Cited by 149
Self-citationEfficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
Abdul‐Ghani, M. A., Norton, L., & DeFronzo, R. A. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0275-6 · Cited by 123
Self-citationBriand, F., Mayoux, E., Brousseau, E., Burr, N., Urbain, I., Costard, C., Mark, M., & Sulpice, T. (2016) · Diabetes · doi:10.2337/db16-0049 · Cited by 118
Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy
Yamout, H., Perkovic, V., Davies, M. J., Woo, V. C., de Zeeuw, D., Mayer, C., Vijapurkar, U., Kline, I., Usiskin, K., Meininger, G. E., et al. (2014) · American Journal of Nephrology · doi:10.1159/000364909 · Cited by 115
Nauck, M. A., Prato, S. D., Durán-Garcia, S., Rohwedder, K., Langkilde, A. M., Sugg, J. E., & Parikh, S. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12327 · Cited by 114
Dziuba, J., Alperin, P., Racketa, J., Iloeje, U. H., Goswami, D., Hardy, E., Perlstein, I., Grossman, H. L., & Cohen, M. M. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12261 · Cited by 97
Sarashina, A., Koiwai, K., SEMAN, L. J., Yamamura, N., Taniguchi, A., Negishi, T., Sesoko, S., Woerle, H. J., & Dugi, K. A. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-082 · Cited by 86
Polidori, D., Sha, S., Ghosh, A., Plum‐Mörschel, L., Heise, T., & Rothenberg, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4205 · Cited by 86
Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats.
Kamran, M., Peterson, R. G., & Dominguez, J. H. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v86943 · Cited by 84
EMPA-REG – the “diuretic hypothesis”
McMurray, J. J. V. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.012 · Cited by 83
Zambrowicz, B., Ding, Z., Ogbaa, I., Frazier, K., Banks, P. L., Turnage, A., Freiman, J. P., Smith, M. G., Ruff, D. A., Sands, A., et al. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.01.010 · Cited by 79
Ali, S., Ussher, J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., & Drucker, D. J. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.005 · Cited by 69
Scheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.05.006 · Cited by 64
Hansen, L., Iqbal, N., Ekholm, E., Cook, W., & Hirshberg, B. (2014) · Endocrine Practice · doi:10.4158/ep14489.or · Cited by 63
Ptaszynska, A., Cohen, S. M., Messing, E. M., Reilly, T. P., JOHNSSON, E. K., & Johnsson, K. M. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0128-9 · Cited by 62
Kimura, G. (2016) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2016.01.009 · Cited by 57
Scheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.12.005 · Cited by 50
Merovci, A., Abdul‐Ghani, M. A., Mari, A., Solis‐Herrera, C., Xiong, J., Daniele, G., Tripathy, D., & DeFronzo, R. A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2597 · Cited by 48
Self-citationEmpagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
Lamos, E. M., Younk, L. M., & Davis, S. N. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.909407 · Cited by 43
Sotagliflozin as a potential treatment for type 2 diabetes mellitus
Cariou, B., & Charbonnel, B. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1100361 · Cited by 37
Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects
Eldor, R., Daniele, G., Huerta, C., Al-Atrash, M., Adams, J. M., DeFronzo, R. A., Duong, T. Q., Lancaster, J. B., Zirie, M. A., Jayyousi, A., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2706 · Cited by 27
Self-citationEffects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog
Gustavson, S. M., Chu, C. A., Nishizawa, M., Neal, D. W., Farmer, B., Yang, Y., Donahue, E. P., Flakoll, P. J., & Cherrington, A. D. (2004) · Metabolism · doi:10.1016/j.metabol.2004.01.018 · Cited by 22
Systemic hypertension in diabetes mellitus
Felicetta, J. V., & Sowers, J. R. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)91103-4 · Cited by 21
Thuesen, L., Christiansen, J. S., Sørensen, K. E., Ørskov, H., & HENNINGSEN, P. (1988) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365518809085396 · Cited by 18
Cited by
Stefan, N., Häring, H.-U., & Cusi, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 837
Mosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., Murphy, S. A., Heerspink, H. J. L., Zelniker, T. A., Dwyer, J. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30180-9 · Cited by 684
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
Eriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4675-2 · Cited by 396
Metadata
- Authors
- DeFronzo, R. A., Norton, L., & Abdul-Ghani, M.
- Venue
- Nature Reviews Nephrology
- Published
- 2016-12-12
- Volume
- 13
- Issue
- 1
- Pages
- 11-26
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- OpenAlex
- W2560643142
- Cited by
- 553
- References
- 134
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.